Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
31
BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years
Oct
29
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Oct
29
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
Oct
25
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Oct
14
Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior
Oct
13
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
Sep
17
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
Sep
17
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Sep
10
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care